GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer
| Autor: | Hakan Alakus, W Siffert, E. Bollschweiler, D. Vallböhmer, S. P. Mönig, Uta Drebber, K Riemann, Stephan Baldus, A. H. Hölscher, Jan Brabender, Ute Warnecke-Eberz, R. Metzger |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Esophageal Neoplasms Histopathological response Gastroenterology Text mining Internal medicine Chromogranins GTP-Binding Protein alpha Subunits Gs Genetics medicine GNAS complex locus Humans Aged Pharmacology Polymorphism Genetic biology business.industry Middle Aged Esophageal cancer medicine.disease Combined Modality Therapy Chemotherapy Adjuvant biology.protein Molecular Medicine Female Radiotherapy Adjuvant business |
| Zdroj: | The Pharmacogenomics Journal. 9:202-207 |
| ISSN: | 1473-1150 1470-269X |
| Popis: | Recent studies have shown an association between the GNAS1 T393C polymorphism and clinical outcome for various solid tumors. In this study, we genotyped 51 patients from an observational trial on cisplatin/5-FU-based neoadjuvant radiochemotherapy of locally advanced esophageal cancer (cT2-4, Nx, M0) and genotyping was correlated with histomorphological tumor regression. The C-allele frequency in esophageal cancer patients was 0.49. Pearson's chi(2)-test showed a significant (P0.05) association between tumor regression grades and T393C genotypes. Overall, 63% of the patients in the T-allele group (TT+CT) were minor responders with more than 10% residual vital tumor cells in resection specimens, whereas T(-) genotypes (CC) showed a major histopathological response with less than 10% residual vital tumor cells in 80%. The results support the role of the T393C polymorphism as a predictive molecular marker for tumor response to cisplatin/5-FU-based radiochemotherapy in esophageal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|